Ketorolac, intramuscular — Competitive Intelligence Brief

Ketorolac, intramuscular (Ketorolac, intramuscular) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management / Anesthesia.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Anesthesia Small molecule

Target snapshot

Ketorolac, intramuscular (Ketorolac, intramuscular) — The University of Texas Medical Branch, Galveston. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketorolac, intramuscular TARGET	Ketorolac, intramuscular	The University of Texas Medical Branch, Galveston	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Bromfenac Ophthalmic Solution B	Bromfenac Ophthalmic Solution B	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Diclofenac 1%	Diclofenac 1%	Daré Bioscience, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Ibuprofen (Advil)	Ibuprofen (Advil)	Bayer	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Novel strategy Aspirin	Novel strategy Aspirin	Assistance Publique - Hôpitaux de Paris	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Active ASA	Active ASA	Hamilton Health Sciences Corporation	marketed	Nonsteroidal Anti-Inflammatory Drug (NSAID)	Cyclooxygenase (COX) enzymes
aspirin + celecoxib	aspirin + celecoxib	Seoul National University Hospital	marketed	Nonsteroidal anti-inflammatory drug (NSAID) combination	COX-1 and COX-2 enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class